Display options
Cite
Kang A, Jardine MJ. SGLT2 inhibitors may offer benefit beyond diabetes. Nat Rev Nephrol. 2021;17(2):83-84doi: 10.1038/s41581-020-00391-2.
Kang, A., & Jardine, M. J. (2021). SGLT2 inhibitors may offer benefit beyond diabetes. Nature reviews. Nephrology, 17(2), 83-84. https://doi.org/10.1038/s41581-020-00391-2
Kang, Amy, and Jardine, Meg J. "SGLT2 inhibitors may offer benefit beyond diabetes." Nature reviews. Nephrology vol. 17,2 (2021): 83-84. doi: https://doi.org/10.1038/s41581-020-00391-2
Kang A, Jardine MJ. SGLT2 inhibitors may offer benefit beyond diabetes. Nat Rev Nephrol. 2021 Feb;17(2):83-84. doi: 10.1038/s41581-020-00391-2. PMID: 33361782.
Copy Download .nbib Format: NLM
Share it on

Nat Rev Nephrol. 2021 Feb;17(2):83-84. doi: 10.1038/s41581-020-00391-2.

SGLT2 inhibitors may offer benefit beyond diabetes.

Nature reviews. Nephrology

Amy Kang, Meg J Jardine

Affiliations

  1. Renal and Metabolic Division, The George Institute for Global Health, UNSW Sydney, Sydney, Australia.
  2. Prince of Wales Hospital, Sydney, Australia.
  3. Renal and Metabolic Division, The George Institute for Global Health, UNSW Sydney, Sydney, Australia. [email protected].
  4. NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia. [email protected].
  5. Concord Repatriation General Hospital, Sydney, Australia. [email protected].

PMID: 33361782 DOI: 10.1038/s41581-020-00391-2

[No abstract available.]

References

  1. McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019). - PubMed
  2. Petrie, M. C. et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA 323, 1353–1368 (2020). - PubMed
  3. Jhund, P. S. et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation https://doi.org/10.1161/CIRCULATIONAHA.120.050391 (2020). - PubMed
  4. Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019). - PubMed
  5. Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020). - PubMed
  6. Anker, S. D. et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status - results from the EMPEROR-reduced trial. Circulation (2020). - PubMed
  7. Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020). - PubMed
  8. Wheeler, D. C. et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol. Dial. Transplant. 35, 1700–1711 (2020). - PubMed
  9. Lytvyn, Y. et al. Sodium glucose cotransporter-2 inhibition in heart failure. Circulation 136, 1643–1658 (2017). - PubMed
  10. Packer, M. Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation 136, 1548–1559 (2017). - PubMed

Substances

MeSH terms

Publication Types